|
gptkbp:instanceOf
|
gptkb:drug
Sedative
Anticonvulsant
Barbiturate
|
|
gptkbp:ATCCode
|
N03AA02
|
|
gptkbp:bioavailability
|
90–100%
|
|
gptkbp:CASNumber
|
50-06-6
|
|
gptkbp:chemicalFormula
|
C12H12N2O3
|
|
gptkbp:contraindication
|
gptkb:Porphyria
Severe liver impairment
Severe respiratory depression
|
|
gptkbp:discoveredBy
|
gptkb:Heinrich_Emil_Fischer
|
|
gptkbp:discoveredIn
|
1912
|
|
gptkbp:eliminationHalfLife
|
53–118 hours
|
|
gptkbp:excretion
|
Urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phenobarbitone
|
|
gptkbp:interactsWith
|
gptkb:Warfarin
gptkb:Doxycycline
Oral contraceptives
Corticosteroids
|
|
gptkbp:IUPACName
|
5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
|
|
gptkbp:legalStatus
|
Prescription only
Controlled substance
|
|
gptkbp:mechanismOfAction
|
Barbiturate receptor agonist
Enhances GABAergic inhibition
|
|
gptkbp:meltingPoint
|
174°C
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
4598
4763
CHEMBL41
DB01174
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
Intramuscular
Intravenous
|
|
gptkbp:sideEffect
|
Hypotension
Cognitive impairment
Dependence
Drowsiness
Respiratory depression
|
|
gptkbp:synonym
|
gptkb:Phenobarbital
gptkb:Luminal
Phenobarbiton
|
|
gptkbp:UNII
|
Y3J0XW6W1E
|
|
gptkbp:usedFor
|
Epilepsy
Seizures
Sedation
Status epilepticus
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Phenobarbital
|
|
gptkbp:bfsLayer
|
7
|